within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX11_Pitolisant;
model Pitolisant 
   extends Pharmacolibrary.Drugs.ATC.N.N07XX11;

  annotation(Documentation(
    info ="<html><body><p>Pitolisant is a selective histamine H3 receptor inverse agonist/antagonist used to treat excessive daytime sleepiness in adults with narcolepsy with or without cataplexy. It is an approved medication in the European Union and the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers under oral administration. Values are rounded means reported after single doses, both sexes included.</p><h4>References</h4><ol><li><p>Syed, YY (2016). Pitolisant: First Global Approval. <i>Drugs</i> 76(13) 1313–1318. DOI:<a href=&quot;https://doi.org/10.1007/s40265-016-0620-1&quot;>10.1007/s40265-016-0620-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27438291/&quot;>https://pubmed.ncbi.nlm.nih.gov/27438291</a></p></li><li><p>Bruhn, C (2016). [Pitolisant for the treatment of narcolepsy with or without cataplexy]. <i>Medizinische Monatsschrift fur Pharmazeuten</i> 39(8) 324–329. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29984945/&quot;>https://pubmed.ncbi.nlm.nih.gov/29984945</a></p></li><li><p>Nirogi, R, et al., &amp; Vurimindi, H (2013). LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. <i>Biomedical chromatography : BMC</i> 27(11) 1431–1437. DOI:<a href=&quot;https://doi.org/10.1002/bmc.2939&quot;>10.1002/bmc.2939</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23760876/&quot;>https://pubmed.ncbi.nlm.nih.gov/23760876</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Pitolisant;
